DNTH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 146884 min ago

@ $22.91

Wydano: 8 vas. 2024 @ 19:13

Zwrot: 13.75%

Poprzedni sygnał: vas. 7 - 22:54

Poprzedni sygnał: Sprzedaż

Zwrot: -4.78 %

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 20:06):

Stats
Dzisiejszy wolumen	20 192.00
Średni wolumen	160 941
Kapitalizacja rynkowa	764.85M
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $-0.430 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.24
ATR14	$0.121 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Fairmount Funds Management Llc	Buy	58 857	Common Stock
2024-04-01	Fairmount Funds Management Llc	Sell	58 857	Common Stock
2024-01-24	Carr Edward	Buy	80 000	Stock Option (Right to Buy)
2024-01-24	Veness Adam M	Buy	110 000	Stock Option (Right to Buy)
2024-01-24	Randhawa Simrat	Buy	120 000	Stock Option (Right to Buy)

INSIDER POWER
97.86
Last 18 transactions
Buy: 6 045 948 \| Sell: 58 857

Wolumen Korelacja

Długi: -0.03 (neutral)

Krótki: -0.06 (neutral)

Signal:(57.088) Neutral

Dianthus Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dianthus Therapeutics, Korelacja - Waluta/Towar

0.24
( neutral )

0.14
( neutral )

0.00
( neutral )

0.04
( neutral )

-0.37
( neutral )

-0.08
( neutral )

Dianthus Therapeutics, Finanse

Annual	2023
Przychody:	$2.83M
Zysk brutto:	$2.47M (87.44 %)
EPS:	$-8.45

FY	2023
Przychody:	$2.83M
Zysk brutto:	$2.47M (87.44 %)
EPS:	$-8.45

FY	2022
Przychody:	$6.42M
Zysk brutto:	$6.27M (97.71 %)
EPS:	$-32.57

Financial Reports:

No articles found.

Dianthus Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Dianthus Therapeutics,

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.